Abstract:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Analogous to the border customs, liver mainly functions as a filter to detoxify chemicals and metabolite administered orally or intravenously. Besides, liver cancer cells overexpress the drug exporters which cause high drug effluxion from liver cancer cells, leading to chemoresistance and a diminished chemotherapeutic effect on liver cancer. Recently, we found that RNA nanoparticles display rubber-like property that can rapidly deliver therapeutics to tumor site efficiently and the rest of the RNA nanoparticle were cleared by renal excretion within half hour after systemic injection (Ghimire et al., ACS Nano). Therefore, we designed a new multivalent RNA nanoparticle harboring three copies of hepatocyte targeting-ligands, one copy of miR122, and 24 copies of Paclitaxel to overcome the drug effluxion and chemoresistance thus, synergistically treat HCC. The hepatocyte targeting ligands introduce tumor specificity to the RNA nanoparticles as they selectively bind and internalize into liver cancer cells. The rubber-like RNA nanoparticles allow for enhanced targeting ability to the HCC tumors. The RNA nanoparticles carrying miR122 and PTX were delivered to the liver cancer cells efficiently due to their rubber-like property to enhance their EPR and transcytosis effect as well as the receptor-mediated endocytosis by hepatocyte targeting-ligands. The miR122 efficiently silenced the drug exporters and the oncogenic protein. The synergistic effect between miR122 and PTX was confirmed by HSA (Highest Single Agent) synergy model. IC50 was determined to be 460 nM. In vivo studies on mice xenografts revealed that the RNA nanoparticle predominantly accumulated in HCC tumor sites and efficiently inhibited the tumor growth after multiple IV injection. This demonstrates the potential of the rubber-like multivalent RNA nanoparticles to conquest the liver cancer, a currently incurable lethal disease.

Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma

MicroRNA‐122 Suppresses Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma by Directly Targeting Wnt/β‐catenin Pathway

Single‐Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR‐122 Function in Hepatocellular Carcinoma Cells by using “Smart” Mesoporous Silica Nanoparticles

THE CHARACTERISTICS AND FUNCTIONS OF MOLECULAR BIOLOGY FOR LIVER-SPECIFIC Mir-122

Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy.

Simple and Rational Design of a Polymer Nano-Platform for High Performance of HCV Related Mir-122 Reduction in the Liver

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Evaluation of Mir-122-regulated Suicide Gene Therapy for Hepatocellular Carcinoma in an Orthotopic Mouse Model

Hydrogel-based miR-192 delivery inhibits the development of hepatocellular carcinoma by suppressing the GSK3β/Wnt/β-catenin pathway

Tumor-triggered Personalized Microrna Cocktail Therapy for Hepatocellular Carcinoma

A PEGylated Megamer-Based Microrna Delivery System Activatable by Stepwise Microenvironment Stimulation

Therapeutics Based on microRNA: A New Approach for Liver Cancer

Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance

Doxifluridine-based Pharmacosomes Delivering Mir-122 As Tumor Microenvironments-Activated Nanoplatforms for Synergistic Treatment of Hepatocellular Carcinoma.

PLGA-based Dual Targeted Nanoparticles Enhance Mirna Transfection Efficiency in Hepatic Carcinoma

Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma

Ultrasound-triggered release of miR-199a-3p from liposome nanobubbles for enhanced hepatocellular carcinoma treatment

Co-delivery of camptothecin and MiR-145 by lipid nanoparticles for MRI-visible targeted therapy of hepatocellular carcinoma

Aptamer and Peptide-Modified Lipid-Based Drug Delivery Systems in Application of Combined Sequential Therapy of Hepatocellular Carcinoma

Tumor-triggered MicroRNA Cocktail Therapy for Hepatocellular Carcinoma